Bryn Mawr Capital Management LLC Purchases 16,785 Shares of Abbott Laboratories (NYSE:ABT)

Bryn Mawr Capital Management LLC grew its position in Abbott Laboratories (NYSE:ABT) by 22.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 92,284 shares of the healthcare product maker’s stock after purchasing an additional 16,785 shares during the quarter. Bryn Mawr Capital Management LLC’s holdings in Abbott Laboratories were worth $10,158,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of ABT. Rise Advisors LLC bought a new stake in shares of Abbott Laboratories in the 4th quarter valued at $37,000. Stonehage Fleming Financial Services Holdings Ltd bought a new stake in shares of Abbott Laboratories in the 3rd quarter valued at $40,000. Cornerstone Planning Group LLC boosted its stake in shares of Abbott Laboratories by 79.4% in the 3rd quarter. Cornerstone Planning Group LLC now owns 454 shares of the healthcare product maker’s stock valued at $44,000 after purchasing an additional 201 shares during the last quarter. Legacy Financial Group LLC bought a new position in Abbott Laboratories during the third quarter worth $46,000. Finally, Briaud Financial Planning Inc bought a new position in Abbott Laboratories during the third quarter worth $48,000. 75.18% of the stock is owned by institutional investors.

Insider Activity

In other news, EVP Andrea F. Wainer sold 42,500 shares of the stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $112.50, for a total value of $4,781,250.00. Following the completion of the sale, the executive vice president now owns 65,027 shares in the company, valued at $7,315,537.50. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, EVP Andrea F. Wainer sold 12,500 shares of the firm’s stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $120.00, for a total transaction of $1,500,000.00. Following the completion of the sale, the executive vice president now owns 78,704 shares in the company, valued at $9,444,480. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Andrea F. Wainer sold 42,500 shares of the firm’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $112.50, for a total transaction of $4,781,250.00. Following the sale, the executive vice president now owns 65,027 shares of the company’s stock, valued at approximately $7,315,537.50. The disclosure for this sale can be found here. Insiders sold a total of 56,435 shares of company stock worth $6,451,298 over the last quarter. Insiders own 1.10% of the company’s stock.

Abbott Laboratories Stock Performance

ABT opened at $107.51 on Friday. The company has a current ratio of 1.64, a quick ratio of 1.16 and a debt-to-equity ratio of 0.35. The company’s fifty day moving average price is $113.64 and its two-hundred day moving average price is $108.03. Abbott Laboratories has a 1-year low of $89.67 and a 1-year high of $121.64. The company has a market cap of $186.55 billion, a price-to-earnings ratio of 33.49, a PEG ratio of 2.57 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Wednesday, April 17th. The healthcare product maker reported $0.98 EPS for the quarter, beating the consensus estimate of $0.96 by $0.02. The company had revenue of $9.96 billion during the quarter, compared to the consensus estimate of $9.88 billion. Abbott Laboratories had a net margin of 13.96% and a return on equity of 20.32%. The firm’s revenue for the quarter was up 2.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.03 earnings per share. On average, analysts expect that Abbott Laboratories will post 4.62 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 15th. Stockholders of record on Monday, April 15th will be issued a $0.55 dividend. The ex-dividend date is Friday, April 12th. This represents a $2.20 annualized dividend and a dividend yield of 2.05%. Abbott Laboratories’s dividend payout ratio is currently 68.54%.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on ABT shares. Royal Bank of Canada cut their target price on shares of Abbott Laboratories from $128.00 to $125.00 and set an “outperform” rating on the stock in a research note on Thursday, April 18th. Barclays cut their target price on shares of Abbott Laboratories from $141.00 to $140.00 and set an “overweight” rating on the stock in a research note on Monday, April 22nd. Raymond James reissued a “buy” rating and set a $124.00 target price on shares of Abbott Laboratories in a research note on Wednesday. Citigroup increased their target price on shares of Abbott Laboratories from $126.00 to $128.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Finally, Evercore ISI upped their price objective on shares of Abbott Laboratories from $120.00 to $125.00 and gave the stock an “outperform” rating in a report on Thursday, April 4th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, Abbott Laboratories has a consensus rating of “Moderate Buy” and an average price target of $121.50.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.